STT stands for sclerothalamotomy and is an ab interno-glaucoma operation using bipolar RF diathermia. STT was first presented by Bojan Pajic and Gregoris Pallas in 1999. From a first study group (53 eyes) in 2002, there are now long-term 72 month results . From an average pre-operative value of 25.6 ± 2.3 mmHg the pressure sank to 14.8 ± 1.7 mmHg, the pressure-lowering eyedrops that were applied on average were reduced from 2.6 ± 1.0 to 0.21 ± 0.53.
These are results that, in contrast to methods like trabeculectomy or viscocanalostomy, are really very promising. In addition, STT is attractive for the following reasons:
- High success rate
- Effective, lasting lowering of pressure
- Very low complication rate
- Particularly easy and fast intervention
- No application of anti-metabolites or needling
Gold Shunt - GMS PLUS+
Gold Shunt Overview
The Gold Shunt, GMS PLUS+, is a novel, minimally invasive device that has the potential to advance the surgical treatment of glaucoma. Developed in collaboration with experienced engineers and leading glaucoma surgeons, the device is the first biocompatible, pure gold implant that uses the eye's natural pressure differential to reduce intraocular pressure (IOP). Differentiated from other surgical glaucoma options, the results are achieved without creating a bleb, a common source of serious medical complications.
Read more: Gold Shunt for Glaucoma